Adult Dosing
EGFR-expressing metastatic colorectal CA
- Recommended dose: 6 mg/kg IV over 60 mins q14 days [Max: 1000 mg over 90 mins]
- Dose modifications for infusion reactions for the duration of that infusion:
- Mild or moderate (grade 1 or 2) infusion reaction: Reduce infusion rate by 50%
- Severe (grade 3 or 4) infusion reactions: Immediately and permanently discontinue the treatment
- Dose modifications for dermatologic toxicity:
- Dermatologic toxicity
grade 3: Withhold treatment - Dermatologic toxicity grade 2 after 1 month of withholding treatment : Permanently discontinue treatment
- Dermatologic toxicity
grade 2: resume treatment at 50% of the original dose
- Note: If toxicities recur, permanently discontinue the drug
Pediatric Dosing
- The safety and effectiveness in pediatric patients have not been established
[Outline]
See Supplemental Patient Information
- Dermatologic toxicities including dermatitis acneiform, pruritus, erythema, rash, skin exfoliation, paronychia, dry skin and skin fissures are reported in 89% of patients and severe dermatologic toxicities complicated by infection including sepsis, septic death are reported in 12% of patients receiving panitumumab monotherapy [US Black Box Warning]
- Discontinue treatment in those who develop dermatologic or soft tissue toxicity and monitor for inflammatory or infectious sequelae in patients with severe toxicities
- Severe infusion reactions including anaphylaxis, bronchospasm, fever, chills and hypotension occurred in approximately 1% of patients. Stop infusion if severe infusion reactions occurs [US Black Box Warning]
- Reduce infusion rate by 50% in patients experiencing a mild or moderate (grade 1 or 2) infusion reaction for the duration of that infusion
- Immediately and permanently discontinue panitumumab infusion in patients experiencing severe (grade 3 or 4) infusion reactions
- Panitumumab is indicated for treatment of metastatic colorectal cancer that expresses EGFR (epidermal growth factor receptor) and has failed conventional treatments
- Panitumumab is not indicated for use in combination with chemotherapy
- Discontinue the drug in patients developing interstitial lung disease, pneumonitis, or lung infiltrates
- Monitor electrolytes during and for 8 weeks after completion of therapy and institute appropriate treatment
- Avoid sunlight exposure during the treatment and 2 months after discontinuation of the treatment
- Avoid pregnancy during treatment and until 6 months after discontinuation
- Avoid breastfeeding during treatment and until 2 months after discontinuation
Cautions: Use cautiously in
- Pulmonary fibrosis
- History of interstitial pneumonitis
- Diarrhea
- Lactation
Supplemental Patient Information
- Adequate contraception should be advised in both males and females while receiving the drug and for 6 months after the last dose
Pregnancy Category:C
Breastfeeding: Safety unknown; because of the potential for possible serious adverse reactions in nursing infants a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Pricing data from www.DrugStore.com in U.S.A.
- Vectibix 400 MG/20ML SOLN [Vial] (AMGEN)
20 20ml = $4349.4
60 20ml = $12943.1 - Vectibix 100 MG/5ML SOLN [Vial] (AMGEN)
5 5ml = $951.99
15 5ml = $2706.87
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
